There is currently no generic Halaven (eribulin) available because a patent prevents any generic forms from being manufactured in the United States. Eisai, Inc., has exclusive rights to market the medication until 2019, which is the earliest date that a generic version could become available. It is important to note that eribulin is the "generic name" of Halaven, not a generic version of it.
Can I Buy Generic Halaven?
Halaven™ (eribulin mesylate) is a chemotherapy medication approved for the treatment of breast cancer. It belongs to a group of medications known as microtubule inhibitors. It is used when other types of cancer treatment have failed.
Halaven is made by Eisai, Inc. It is currently under the protection of a patent that prevents any generic products from being manufactured in the United States.
When Will a Generic Version Be Available?
The first patent for Halaven is currently set to expire in June 2019. This is the earliest predictable date that a generic version could become available.
However, circumstances could extend this exclusivity period. This could include such things as lawsuits or other patents for specific Halaven uses. Once the patent expires, several companies will likely begin manufacturing generic Halaven products.
Is Eribulin a Generic Halaven?
No -- eribulin is the active ingredient in Halaven, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Halaven [package insert]. Woodcliff Lake, NJ: Eisai, Inc.;2010 November.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed January 6, 2011.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click